Pharmacokinetic (PK) and Safety Study of Iptacopan (LNP023) in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Matched Control Healthy Participants With Normal Hepatic Function.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

38 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-11-10

Study Completion Date

2022-06-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This was an open-label, single dose parallel group study to evaluate the PK of iptacopan in participants with mild, moderate, and severe hepatic impairment compared to matched healthy control participants.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Evaluate ASP0367 in Participants With Mild/Moderate Hepatic Impairment Compared to Participants With Normal Hepatic Function

NCT04942964

Hepatic Impairment Healthy Volunteers

COMPLETED PHASE1

Study to Evaluate the Safety, Tolerability, and PK of Pacritinib

NCT05552183

Hepatic Impairment

COMPLETED PHASE1

A Study to Evaluate the Effect of Hepatic Impairment on JNJ-73763989

NCT04208386

Hepatic Impairment

COMPLETED PHASE1

A Study to Evaluate the Pharmacokinetics of ACT-541468 in Subjects With Mild, Moderate, and Severe Hepatic Impairment

NCT03713242

Hepatic Impairment

COMPLETED PHASE1

A Study of EDP-305 in Subjects With Mild and Moderate Hepatic Impairment Compared With Normal Healthy Volunteers

NCT03207425

NASH

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study comprised of a screening period up to 28 days, one Baseline evaluation on Day -1, a single dose administration of 200 mg of iptacopan followed by PK sampling to 240 hr, and an End-of-Study (EOS) visit (Day 11). All participants had a post study safety follow-up call conducted approximately 30 days after last administration of study drug.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatic Impairment

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Healthy participants

Iptacopan 200 mg single dose

Group Type EXPERIMENTAL

Iptacopan

Intervention Type DRUG

Single oral dose of iptacopan 200 mg oral capsules

Mild hepatic impairment patients

Iptacopan 200 mg single dose

Group Type EXPERIMENTAL

Iptacopan

Intervention Type DRUG

Single oral dose of iptacopan 200 mg oral capsules

Moderate hepatic impairment patients

Iptacopan 200 mg single dose

Group Type EXPERIMENTAL

Iptacopan

Intervention Type DRUG

Single oral dose of Iptacopan 200 mg oral capsules

Severe hepatic impairment patients

Iptacopan 200 mg single dose

Group Type EXPERIMENTAL

Iptacopan

Intervention Type DRUG

Single oral dose of Iptacopan 200 mg oral capsules

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Iptacopan

Single oral dose of iptacopan 200 mg oral capsules

Intervention Type DRUG

Iptacopan

Single oral dose of iptacopan 200 mg oral capsules

Intervention Type DRUG

Iptacopan

Single oral dose of Iptacopan 200 mg oral capsules

Intervention Type DRUG

Iptacopan

Single oral dose of Iptacopan 200 mg oral capsules

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

LNP023 LNP023 LNP023 LNP023

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Participants eligible for inclusion in this study met the following key criteria:

* Written informed consent was obtained before performing any assessment.
* Male participants and female participants of non-childbearing potential 18 to 75 years of age (inclusive).
* Participants were to weigh at least 55 kg to participate in the study and were to have a body mass index (BMI) within the range of 18 to 35 kg/m2 for healthy participants.

For hepatic impairment participants without overt ascites, the BMI was to be within the range of 18 to 40 kg/m2. For hepatic impairment participants with overt ascites, the BMI was to be within the range of 18 to 45 kg/m2.

* Ability to communicate well with the Investigator, to understand and comply with the requirements of the study.
* Participant was willing to remain in the clinical research unit as required by the protocol

Exclusion Criteria

Participants meeting any of the following criteria were excluded from this study:

* Use of other investigational drugs within the last 30 days or 5 half-lives prior to dosing, whichever was longer.
* History of hypersensitivity to the investigational compound/compound class or its excipients being used in this study.
* Pregnant or nursing (lactating) women. Pregnancy was defined as the state of a female after conception and until termination of gestation, confirmed by a positive human chorionic gonadotropin (hCG) laboratory test.
* Known history of, or current clinically significant arrhythmias, history of prolonged QT correction formula (QTcF) interval or QTcF \> 450 msec (males) or QTcF \> 460 msec (females) at screening in healthy participants and history of prolonged QTcF interval or QTcF \> 470 msec (males) or QTcF \> 480 msec (females) at screening in participants with hepatic impairment.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes